
Read More
68% returns in just 3 months: Pharma stock locked in the 5% upper circuit, ...
The stock has given almost multibagger returns of over 94.08 per cent from its 52-week low of Rs 270...

The stock has given almost multibagger returns of over 94.08 per cent from its 52-week low of Rs 270...

In the last one year the stock has given 2 per cent returns, while in the last five years, it has gi...

The stock is up by 70 per cent in just 1 year and generated multibagger returns of 1,280 per cent in...

This approval, for its Enoxaparin product in pre-filled syringes, comes from the largest pharmaceuti...

The marketing approval for Enoxaparin in Saudi Arabia is anticipated to pave the way for similar aut...

In Q4FY23, the company reported a 4708.7 per cent increase in net profit YoY....

The shares of the company saw a spurt in volume by more than 1.40 times on BSE. The stock has a PE o...

Meropenem, a vital antibiotic for life-threatening infections, contributes 40 per cent to total sale...

On Thursday, the Sensex fell by 139 points to close at 59,605.80, while the Nifty 50 dropped by marg...

At 12.15 pm on Wednesday, the core equity indices i.e., Sensex and Nifty 50 were recovering amidst r...